Effects of statins upon bone mineral density in postmenopausal women with hypercholesterolemia

National Medical Journal of China

Volumn 93, Issue 29, 2013, Pages 2309-2311

  Zhao, Chen ^a   Bi, Qing ^a   Hu, Jin Tao ^b   Xia, Bing ^a   Ying, Qi Feng ^b   Zhu, Dan Jie ^a   Zhang, Shui Jun ^a   Gu, Hai Feng ^a   Hong, Jian Fei ^a   Qiu, Bin Song ^a   Chen, Yu ^a  

^a ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b NONE

Author keywords

Bone density; Hydroxymethylglutaryl CoA reductase inhibitors; Osteoporosis, postmenopausal

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; ATORVASTATIN; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROCOLLAGEN C PROTEINASE;

ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; CONTROLLED STUDY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PROSPECTIVE STUDY;

BONE DENSITY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; POSTMENOPAUSE; PROCOLLAGEN; PROSPECTIVE STUDIES;

EID: 84883385248     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2013.29.017     Document Type: Article

References (14)

1. Kilicoglu S S, Erdemli E. New addition to the statin's effect. J Trauma, 2007, 63: 187-191.
2. Adah F, Benghuzzi H, Tucci M, et al. Cholesterol production inhibitor (statin) increased bone healing in surgically created femoral defect in an animal model. Biomed Sci Instrum, 2007, 43: 95-103.
3. Tsartsalis A N, Dokos C, Kaiafa G D, et al. Statins, bone formation and osteoporosis: hope or hype? Hormones, 2012, 11: 126-139.
4. 2008, 14: 583-586.
5. Solomon D H, Finhelstein J S, Wang P S, et al. Statin lipid-lowering drugs and bone mineral density. Pharmacoepidemiol Drug Saf, 2005, 14: 219-226.
6. Uzzan B, Cohen R, Nicolas P, et al. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone, 2007, 40: 1581-1587.
7. Lupattelli G, Scarponi A M, Vaudo G, et al. Simvastatin increases bone mineral density in hypercholesterolemic postmenopausal women. Metabolism, 2004, 53: 744-748.
8. Schoofs M W, Sturkenboom M C, van der Klift M, et al. HMG2CoA reductase inhibitors and the risk of vertebral fracture. J Bone Miner Res, 2004, 19: 1525-1530.
9. Rejnmark L, Olsen M L, Johnsen S P, et al. Hip fracture risk in statin users a population-based Danish case-control study. Osteoporos Int, 2004, 15: 452-458.
10. Pritchett J W. Statin therapy decreases the risk of osteon ecrosis in patients receiving steroids. Clin Orthop Related Res, 2001, 386: 173-178.
11. Cremers S, Garnero P. Biochemical markers of bone turn-over in the clinical development of drugs for osteoporosis and metastasis bone disease: potential uses and pitfalls. Drugs, 2006, 66: 2031-2058.
12. Dang Z C, Audinot V, Papapoulos S E, et al. Peroxisome proliferator-activated receptor gamma (PPARγ) as a molecular target for the soy phytoestrogen genistein. J Cell Biochem, 2003, 278: 962-967.
13. Corte R L, Trotta F, Adami S. Glucocorticoid receptors and bone. Current Pharmaceut Design, 2010, 16: 3586-3592.
14. Hyun-Ju Kim. New understanding of glucocorticoid action in bone cells. BMB Rep, 2010, 43: 527-529.